Your browser doesn't support javascript.
loading
Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination.
Loyal, Lucie; Braun, Julian; Henze, Larissa; Kruse, Beate; Dingeldey, Manuela; Reimer, Ulf; Kern, Florian; Schwarz, Tatjana; Mangold, Maike; Unger, Clara; Dörfler, Friederike; Kadler, Shirin; Rosowski, Jennifer; Gürcan, Kübrah; Uyar-Aydin, Zehra; Frentsch, Marco; Kurth, Florian; Schnatbaum, Karsten; Eckey, Maren; Hippenstiel, Stefan; Hocke, Andreas; Müller, Marcel A; Sawitzki, Birgit; Miltenyi, Stefan; Paul, Friedemann; Mall, Marcus A; Wenschuh, Holger; Voigt, Sebastian; Drosten, Christian; Lauster, Roland; Lachman, Nils; Sander, Leif-Erik; Corman, Victor M; Röhmel, Jobst; Meyer-Arndt, Lil; Thiel, Andreas; Giesecke-Thiel, Claudia.
Afiliación
  • Loyal L; Si-M/"Der Simulierte Mensch," a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Braun J; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Henze L; Si-M/"Der Simulierte Mensch," a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Kruse B; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Dingeldey M; Si-M/"Der Simulierte Mensch," a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Reimer U; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Kern F; Si-M/"Der Simulierte Mensch," a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Schwarz T; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Mangold M; Si-M/"Der Simulierte Mensch," a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Unger C; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Dörfler F; JPT Peptide Technologies GmbH, Berlin, Germany.
  • Kadler S; JPT Peptide Technologies GmbH, Berlin, Germany.
  • Rosowski J; Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK.
  • Gürcan K; Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Uyar-Aydin Z; Si-M/"Der Simulierte Mensch," a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Frentsch M; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Kurth F; Si-M/"Der Simulierte Mensch," a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Schnatbaum K; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Eckey M; Si-M/"Der Simulierte Mensch," a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Hippenstiel S; Si-M/"Der Simulierte Mensch," a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Hocke A; Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany.
  • Müller MA; Si-M/"Der Simulierte Mensch," a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Sawitzki B; Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany.
  • Miltenyi S; Si-M/"Der Simulierte Mensch," a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Paul F; Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany.
  • Mall MA; Si-M/"Der Simulierte Mensch," a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Wenschuh H; Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany.
  • Voigt S; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Drosten C; Therapy-Induced Remodeling in Immuno-Oncology, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Lauster R; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Lachman N; Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Sander LE; JPT Peptide Technologies GmbH, Berlin, Germany.
  • Corman VM; JPT Peptide Technologies GmbH, Berlin, Germany.
  • Röhmel J; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Meyer-Arndt L; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Thiel A; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Giesecke-Thiel C; Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Science ; 374(6564): eabh1823, 2021 Oct 08.
Article en En | MEDLINE | ID: mdl-34465633
ABSTRACT
The functional relevance of preexisting cross-immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a subject of intense debate. Here, we show that human endemic coronavirus (HCoV)­reactive and SARS-CoV-2­cross-reactive CD4+ T cells are ubiquitous but decrease with age. We identified a universal immunodominant coronavirus-specific spike peptide (S816-830) and demonstrate that preexisting spike- and S816-830­reactive T cells were recruited into immune responses to SARS-CoV-2 infection and their frequency correlated with anti­SARS-CoV-2-S1-IgG antibodies. Spike­cross-reactive T cells were also activated after primary BNT162b2 COVID-19 messenger RNA vaccination and displayed kinetics similar to those of secondary immune responses. Our results highlight the functional contribution of preexisting spike­cross-reactive T cells in SARS-CoV-2 infection and vaccination. Cross-reactive immunity may account for the unexpectedly rapid induction of immunity after primary SARS-CoV-2 immunization and the high rate of asymptomatic or mild COVID-19 disease courses.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / SARS-CoV-2 / COVID-19 Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Science Año: 2021 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / SARS-CoV-2 / COVID-19 Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Science Año: 2021 Tipo del documento: Article País de afiliación: Alemania